The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)–naive patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial.
 
Guillermo Garcia-Manero
Honoraria - Ascentage Pharma; Bristol-Myers Squibb/Celgene; Curis; Keros Therapeutics; SERVIER; Taiho Oncology
Consulting or Advisory Role - Ascentage Pharma; Bristol-Myers Squibb; Curis; Keros Therapeutics; SERVIER; Taiho Oncology
Research Funding - Abbvie; Bristol-Myers Squibb; Chordia Therapeutics; Curis; Genentech; Jazz Pharmaceuticals; Novartis; Rigel; Stemline Therapeutics; Taiho Oncology; Zentalis
 
Matteo Giovanni Della Porta
No Relationships to Disclose
 
Amer Zeidan
Honoraria - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Consulting or Advisory Role - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; Astex Pharmaceuticals; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Research Funding - Abbvie (Inst); Amgen; Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Geron; Kura Oncology; Novartis (Inst); Otsuka; Shattuck Labs; Syros Pharmaceuticals; Takeda (Inst)
 
Rami Komrokji
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; DSI; Genentech; Geron; Janssen; Jazz Pharmaceuticals; Pharmaessentia; Rigel; Servio; SOBI; Sumitomo Pharma Oncology
Speakers' Bureau - Jazz Pharmaceuticals; Pharmaessentia; Rigel; SERVIER; SOBI
Research Funding - Bristol-Myers Squibb/Celgene (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Jazz Pharmaceuticals; Pharmaessentia
 
Veronika Pozharskaya
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Merck
Research Funding - BMS employee
 
Shelonitda Rose
Employment - BMS Corporation
Stock and Other Ownership Interests - Celgene/Bristol-Myers Squibb
Travel, Accommodations, Expenses - BMS Corporation
 
Karen Keeperman
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Yinzhi Lai
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Sameer Kalsekar
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Barkha Aggarwal
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Dimana Miteva
Employment - Bristol-Myers Squibb
Leadership - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Bristol-Myers Squibb
 
David Valcárcel
Consulting or Advisory Role - Amgen; BMS; Celgene; GlaxoSmithKline; Jazz Pharmaceuticals; NOVARTIS; Pfizer; Sanofi; SOBI; Takeda
Speakers' Bureau - Amgen; Astellas Pharma; Astellas Pharma; BMS; Celgene; Gebro Pharma; GlaxoSmithKline; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis; Pfizer; Sanofi/Aventis; SOBI
Travel, Accommodations, Expenses - Amgen; Celgene; GlaxoSmithKline; Jazz Pharmaceuticals; Pfizer
 
Pierre Fenaux
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
 
Jake Shortt
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Otsuka
Speakers' Bureau - Mundipharma (Inst); Novartis (Inst)
Research Funding - Astex (Taiho) (Inst)
 
Uwe Platzbecker
Honoraria - Abbvie; Celgene/Jazz; Curis; Geron; Janssen
Consulting or Advisory Role - BMS GmbH & Co. KG; Celgene/Jazz; Novartis
Research Funding - Amgen (Inst); BerGenBio (Inst); Celgene (Inst); Curis (Inst); Janssen (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - part of a patent for a TFR-2 antibody (Rauner et al. Nature Metabolics 2019)
Travel, Accommodations, Expenses - Celgene
 
Valeria Santini
Honoraria - Celgene/Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Abbvie; Ascentage Pharma; Celgene/Bristol-Myers Squibb; Curis; Geron; Gilead Sciences; GlaxoSmithKline; Keros Therapeutics; Novartis; Otsuka; SERVIER; Syros Pharmaceuticals
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Celgene; Janssen-Cilag; Jazz Pharmaceuticals